-

SHAREHOLDER ALERT: Robbins LLP Investigates Ipsidy Inc. (AUID) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors it is investigating the officers and directors of Ipsidy Inc. (NASDAQ: AUID) for breaches of fiduciary duties and violations of securities laws. Ipsidy claims to operate an Identity as a Service (IDaaS) platform that delivers a suite of secure, mobile, and biometric identity solutions worldwide.

If you would like more information about Ipsidy Inc.'s misconduct, click here.

Ipsidy Inc. (AUID) Is Accused of Misstating its Sources of Revenue

On December 16, 2021, White Diamond Research published a report alleging that Ipsidy "has nothing going for it" and its claims of being a "pure-play SaaS [software as a service] business" are misleading, as "[n]one of its revenues have been from its SaaS product … and 70% are from low tech, legacy businesses." The report claims the Company's revenues "aren't from its identity verification application" and that its "REAL businesses are selling plastic cards in South Africa and leasing bus ticket kiosks in Colombia." Regarding its financials, the report noted that in the quarter ended September 30, 2021, Ipsidy "had a loss of $5.2M and cash burn of $3.2M" and "will likely be out of cash" soon. Further, Ipsidy did not give any guidance in its Q321 earnings call. Finally, the Company's relationship with its newest customer, Hamilton Reserve Bank, is questionable and did not generate any new revenue in the quarter the relationship was announced.

If you own shares of Ipsidy Inc. (AUID), you have rights. Contact us for more information about your legal options.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Ipsidy Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom